Palliative sedation at the end of life at a tertiary cancer center
The aim of this study was to describe the use of palliative sedation (PS) its indications and outcomes in patients followed up till death by an inpatient palliative care consult team (PCCT) at a tertiary cancer center.
All patients referred for 5 years to the PCCT and followed up till death were eligible for the study. Both PCCT recordings and hospital charts were reviewed and a codified assessment was performed.
Over a total of 2,033 consecutive consults, 129 patients died during admission and were eligible. Eighty-three had the indication to PS, 4% of all consults (95% confidence interval [95%CI], 3% to 5%) and 64% of eligible patients (95%CI, 56% to 73%). PS was more frequently indicated in males and in patients with recurrent dyspnea and recurrent agitation, while it was less frequently indicated in older people and in patients with cerebral metastases and recurrent drowsiness. The most frequent indications to PS were dyspnea (37%) and delirium (31%) alone or combined with other symptoms. PS was successfully achieved in 69 patients; the drugs most frequently used for PS were midazolam (46%), haloperidol (35%), and chlorpromazine (32%) and opioid dose escalation was higher in sedated patients (P < 0.01).
PS is an important intervention in the management of terminal disease by a consulting palliative care team. Improved collaboration and communication between the hospital staff and the PCCT should be offered to meet patients’ needs when PS is required.
KeywordsPalliative sedation Palliative care End-of-life care Cancer
This work was partially funded by the Floriani Foundation of Milan and Associazione Italiana per la Ricerca sul Cancro, grant no. IG9347.
Conflict of interest
The authors have no conflict of interest to declare.
- 2.Cherny NI, Catane R, European Society of Medical Oncology Taskforce on Palliative and Supportive Care (2003) Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer 98:2502–2510PubMedCrossRefGoogle Scholar
- 14.Porta i Sales J (2002) Palliative sedation: clinical aspects. In Gastman (ed) Between technology and humanity. Leuven University Press, Leuven, pp 30–37Google Scholar
- 18.Kirk TW, Mahon MM, Palliative Sedation Task Force of the National Hospice and Palliative Care Organization Ethics Committee (2010) National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients. J Pain Symptom Manage 39:914–923PubMedCrossRefGoogle Scholar
- 24.De Conno F, Caraceni A (1996) Manual of cancer pain. Kluwer Academic Press, DorchrechtGoogle Scholar
- 40.Caraceni A, Bosisio M, Ingham JM (2002) Confusion and delirium. In: Schiff D, Kasari S, Wen PY (eds) Cancer neurology in clinical practice, 2nd ed. Humana, Totowa, pp 65–90Google Scholar
- 43.Pace-Schott EF, Hobson JA (2002) Basic mechanisms of sleep new evidence on the neuroanatomy and neuromodulation of the NREM–REM cycle. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology: the fifth generation of progress. American College of Neuropsychopharmacology, Brentwood, pp 1859–1877Google Scholar